STAMFORD, Conn., Feb. 23 Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that Australia's Therapeutic Goods Administration, the Australian equivalent of the U.S. FDA, has cleared the Zargis StethAssist(TM) and Zargis Cardioscan(TM) devices for sale in Australia.
StethAssist allows healthcare professionals to record and visualize heart, lung and other body sounds and share the findings via the Internet with colleagues. The Cardioscan heart sound analysis software is designed to help physicians analyze cardiac sounds for the identification and classification of suspected heart murmurs, which can be signs of heart disease. Both devices connect wirelessly to a Bluetooth®-enabled digital stethoscope for the recording and playback of sounds.
Zargis Medical was a co-recipient of Popular Science magazine's 2009 "Innovation of the Year" award for Cardioscan. A Popular Science video regarding Cardioscan may be viewed at http://tinyurl.com/popscivideo.
Australia's population of more than 21 million people is served by approximately 48,000 physicians, making the nation an important market for Zargis. In addition, the country's vast physical size, and the fact that 34% of Australia's population resides in rural and remote regions, makes the telemedicine capabilities of StethAssist and Cardioscan a strong fit for the Australian healthcare system. The introduction of these devices into Australia will provide benefits during face-to-face patient encounters and allow healthcare providers to extend the use of auscultation (listening with a stethoscope) through the Internet to situations and environments where face-to-face encounters are not practical.
This clearance allows Zargis to immediately begin marketing StethAssist, Cardioscan and the compatible stethoscope in all Australian states and territories. To order Cardioscan or inquire about distribution opportunities visit www.zargis.com.
About Zargis Medical Corp.
Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through diagnostic support software and innovation. Zargis is majority-owned by Speedus Corp. (NASDAQ: SPDE), and both 3M Company and Siemens Corporate Research, a division of Siemens AG (NYSE: SI), hold equity positions.
For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or [email protected]
, or visit the following Web sites: www.zargis.com and www.speedus.com.
Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.
SOURCE Speedus Corp.